Skip to main content
Article thumbnail
Location of Repository

Morning and evening behavior in children and adolescents treated with atomoxetine once daily for Attention-Deficit/Hyperactivity Disorder (ADHD): Findings from two 24-week, open-label studies

By Peter M Wehmeier, Ralf W Dittmann, Alexander Schacht, Karin Helsberg and Gerd Lehmkuhl
Topics: Research
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. A: Non-stimulant medications in the treatment of ADHD. Eur Child Adolesc Psychiatry 2004, 13(Suppl 1):I102-I116.
  2. (2006). AH: Emotional and behavioral difficulties and impairments in everyday functioning among children with a history of attention-deficit/hyperactivity disorder. Public Health Res Practice and Policy
  3. (2007). AJ: A pilot study for augmenting atomoxetine with methylphenidate: safety of concomitant therapy in children with attention-deficit/hyperactivity disorder. Child Adolesc Psychiatry Ment Health
  4. (2004). AJ: Improvement in health-related quality of life in children with ADHD: an analysis of placebo controlled studies of atomoxetine.
  5. (2004). AJ: Once-daily atomoxetine treatment for children with attention-deficit/ hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics
  6. (2000). Association: Diagnostic and Statistical Manual of Mental Disorders 4th edition. Text Revision (DSM-IV-TR). Washington (DC):
  7. (2001). Atomoxetine ADHD Study Group: Atomoxetine in the treatment of children and adolescents with attention-deficit/ hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics
  8. (2006). BS: Atomoxetine in the management of children with ADHD: effects on quality of life and school functioning. Clin Pediatr (Phila)
  9. (2000). Carlson CL: Social functioning and emotional regulation in the attention deficit hyperactivity disorder subtypes.
  10. (2006). Child ADHD and personality/temperament traits of reactive and effortful control, resiliency and emotionality.
  11. (1996). Child Health Questionnaire (CHQ): A Users Manual Boston: Integrated Therapeutics Group;
  12. (2004). CJ: The link between health-related quality of life and clinical symptoms among children with attention-deficit hyperactivity disorder. J Dev Behav Pediatr
  13. (2000). DISYPS-JK: Diagnostik-System für psychische Störungen im Kindes- und Jugendalter nach ICD-10 und DSM-IV Bern: Verlag Hans Huber;
  14. Ed: ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76–338
  15. (2007). Effectiveness of atomoxetine in children with attention-deficit/hyperactivity disorder and quality of life as perceived by patients, parents and physicians in an open-label study.
  16. (2007). EML: Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents. Meta-analysis and meta-regression analysis. Psychopharmacology (Berl)
  17. (2007). Emotional expression during Attention-Deficit/Hyperactivity Disorders treatment: Initial assessment of treatment effects.
  18. (2005). Faraone SV: Attention-deficit hyperactivity disorder. Lancet
  19. G: Comparative efficacy of once-a-day extended-release methylphenidate, two-times-daily immediate-release methylphenidate, and placebo in a laboratory school setting. Eur Child Adolesc Psychiatry 2004, 13(Suppl 1):I/93-I/101.
  20. (2005). Gilaberte I: Worse quality of life for children with newly diagnosed attention-deficit/hyperactivity disorder, compared with asthmatic and healthy children. Pediatrics
  21. (2006). Group: Factors related to Health-Related Quality of Life (HRQoL) among children with ADHD in Europe at entry into treatment. Eur Child Adolesc Psychiatry
  22. (2002). Health-related quality of life of children and adolescents with mental disorders.
  23. (2001). Heiligenstein JH: Validation of the ADHD Rating Scale as a clinician administered and scored instrument.
  24. (2000). Horwitz RI: Randomized, controlled trials, observational studies, and the hierarchy of research designs.
  25. JS: Emotional well-being in children and adolescents treated with atomoxetine for attention-deficit/hyperactivity disorder: Findings from a patient, parent and physician perspective. Child Adolesc Psychiatry Mental Health
  26. (2002). Major life activity and health outcomes associated with attention-deficit/hyperactivity disorder.
  27. (2006). MH: The Noradrenergic Transmitter System
  28. (1985). National Institutes of Mental Health (NIMH) (Eds): Psychopharmacology Bulletin
  29. (2007). Once-daily atomoxetine for ADHD: Update on evening and morning behavior.
  30. (2002). Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study.
  31. (2001). Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics
  32. reliability, and responsiveness of the DPREMB-R scale for ADHD.
  33. (2007). Research in child and adolescent psychopharmacology: recent accomplishments and new challenges. Psychopharmacology (Berl)
  34. (2005). Revicki DA: Psychometric validation of the child health questionnaire (CHQ) in a sample of children and adolescents with attention-deficit/ hyperactivity disorder. Quality of Life Res
  35. (2006). RT: Atomoxetine Treatment in Children and Adolescents with Attention-Deficit Hyperactivity Disorder: What Are the Long-Term Health-Related Quality-of-Life Outcomes? J Child Adolesc Psychopharmacol
  36. (2004). S: Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder. Pediatrics
  37. (2004). SJ: Efficacy of two once daily methylphenidate formulations compared across dose levels at different times of the day. Preliminary indications from a secondary analysis of the COMACS study data. BMC Psychiatry
  38. (2001). Starfield B: Manual for the Child Health and Illness Profile-Child Edition (CHIP-CETM) Baltimore, MD: The Johns Hopkins University;
  39. (2006). the ADORE Study Group: Cross-cultural reliability and validity of ADHD assessed by the ADHD Rating Scale in a pan-European study. European Child Adolesc Psychiatry
  40. The effect of ADHD on the life of an individual, their family, and community from preschool to adult life. Arch Dis Child 2005, 90 Suppl 1:i2-i7.
  41. (2001). Wigal T: Findings from the NIMH multimodal treatment study of ADHD (MTA): implications and applications for primary care providers. J Dev Behav Pediatr
  42. (2002). WZ: Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.